TRAJAN

Trajan Scientific and Medical

Global Corporate Headquarters
7 Argent Place, Ringwood
Victoria 3134, Australia
Tel: +61 (0) 3 9837 4200
www.trajanscimed.com

Trajan Group Holdings Limited
ACN 152 617 706

ASX RELEASE

Letter to Shareholders

27 March 2026 – Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has today sent a message to shareholders:

Dear Fellow Shareholders,

I hope this message finds you well. I want to take a moment to address the recent decline in our company's valuation, which I understand may be a source of concern for many of you, as it is for me. I want to reassure you that, to our knowledge, there is no fundamental business reason driving this trend.

Throughout the fiscal year 2026, we have provided full year guidance on four occasions from August last year through to late February this year. I want to affirm that, as we approach the end of March, we remain committed to our projections.

Trajan remains watchful for any emerging impacts due to the ongoing conflict in the Middle East and importantly, we are not currently facing any material impacts on our operations, demand, or supply chains. In fact, I am attending one of the largest exhibitions and conferences in our industry, “Analytica,” in Munich, Germany, where the enthusiasm surrounding our solutions continues to grow. The interest in further partnerships and the recognition of Trajan's unique position within the industry have been overwhelmingly positive. While the investment climate may appear challenging, our presence in the global business arena continues to be met with optimism.

Additionally, the margin improvement actions that commenced in November are ongoing.

Please know that management, the board and I are deeply committed to advancing the Trajan strategy to enhance long-term shareholder value. As a major shareholder myself, I share in the concerns that you may feel. Trajan embarked on this journey 15 years ago, and my enthusiasm for our mission remains unwavering, despite our current valuation being dramatically out of line with our industry peers. I am confident that, over time, the true value of our business will be recognized and realized.

Thank you for your continued support and trust in Trajan.

Warm regards,

Stephen Tomisich

Group CEO and Managing Director

Global Corporate Headquarters
7 Argent Place, Ringwood
Victoria 3134, Australia
Tel: +61 (0) 3 9837 4200
www.trajanscimed.com

Trajan Group Holdings Limited
ACN 152 617 706

Analytica 24-27 March 2026, Munich, Germany

Authorised for ASX release by the Disclosure Committee of Trajan Group Holdings Limited

END

Contact:

Investors
investorrelations@trajanscimed.com

Media
media@trajanscimed.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.